ArticleNature2024
Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone.
Abstract readClinical Trial, Phase IControlled Clinical Trial
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.Nature medicine · 2026Trial
- Role ofResearch square · 2026Article
- Realizing the potential of agonistic antibody immunotherapy.Nature reviews. Drug discovery · 2026Review
- The ADP-ribosyltransferases 3 (ART3) is a novel suppressor of pathological cardiac hypertrophy by ribosylating ITGA7.Acta pharmaceutica Sinica. B · 2026Article
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Structural insights into single-pass transmembrane receptor GC-A activation by distinct antihypertensive antibodies.Nature communications · 2026Article
- Single intramuscular injection of self-amplifying RNA ofScience (New York, N.Y.) · 2026Article
- Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Multiomics of Human Obesity and Related Multisystem Diseases.The Journal of clinical endocrinology and metabolism · 2026Article
- Regional and cell specific bioactivity of injectable extracellular matrix biomaterials in myocardial infarction.Nature communications · 2025Article
- Novel pharmacological approaches to lowering blood pressure and managing hypertension.Nature reviews. Cardiology · 2025Review
- Denoising Algorithm for High-Resolution and Large-Range Phase-Sensitive SPR Imaging Based on PFA.Sensors (Basel, Switzerland) · 2025Article
- Review
- Agonist antibody lowers blood pressure.Nature reviews. Drug discovery · 2024Article
Corrections and comments
- Commented on by
Authors and funding
44 authors.
Michael E DunnRegeneron Pharmaceuticals, Tarrytown, NY, USA. michael.dunn@regeneron.com.
Aaron KithcartRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Jee Hae KimRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Andre Jo-Hao HoRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Matthew C FranklinRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Annabel Romero HernandezRegeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID 0000-0002-5119-2319
Jan de HoonCenter for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium.
Wouter BotermansCenter for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium.
Jonathan MeyerRegeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID 0000-0003-4190-9803
Ximei JinRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Dongqin ZhangRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Justin TorelloRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Daniel JasewiczRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Vishal KamatRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Elena GarnovaRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Nina LiuRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Michael RosconiRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Hao PanRegeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID 0009-0007-8325-7141
Satyajit KarnikRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Michael E BurczynskiRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Wenjun ZhengRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Ashique RafiqueRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Jonas B NielsenRegeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Tanima DeRegeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Niek VerweijRegeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Anita PanditRegeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Adam LockeRegeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID 0000-0001-6227-198X
Naga ChalasaniIndiana University School of Medicine & Indiana University Health, Indianapolis, IN, USA.
Olle MelanderThe Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
Tae-Hwi Schwantes-AnDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Penn Medicine Biobank
Aris BarasRegeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID 0000-0002-6830-3396
Luca A LottaRegeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Bret J MusserRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Jason MastaitisRegeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID 0000-0002-9991-3509
Kishor B Devalaraja-NarashimhaRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Andrew J RankinRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Tammy HuangRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Gary HermanRegeneron Pharmaceuticals, Tarrytown, NY, USA.
William OlsonRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Andrew J MurphyRegeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID 0000-0003-4152-4081
George D YancopoulosRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Benjamin A OlenchockRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Lori MortonRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Funding
Quality Assurance and Quality Control Project Management: Improving Submissions and Study Conduct in the Human Subjects Research Prior Approval ProcessUL1TR002529 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI MOE, SHARON M, WIEHE, SARAH ELIZABETH · 2018 to 2022
$27.2MNCATS NIH HHS UL1 TR002529
Abstract
Heart failure is a leading cause of morbidity and mortality
Indexed as
Antibodies, MonoclonalBlood PressureReceptors, Atrial Natriuretic FactorVasoconstrictionVeinsAdultAllosteric RegulationAnimalsDiuresisDogsFemaleHealthy VolunteersHeart FailureHemodynamicsHumansMacaca fascicularisAntibodies, Monoclonalatrial natriuretic factor receptor AReceptors, Atrial Natriuretic Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.